A Support vector machine-based mixture cure model for mixed case interval censored data. [PDF]
Pal S, Aselisewine W.
europepmc +1 more source
ABSTRACT Background Cognitive impairment is a common non‐motor symptom in Multiple Sclerosis (MS), negatively affecting autonomy and Quality of Life (QoL). Innovative rehabilitation strategies, such as semi‐immersive virtual reality (VR) and computerized cognitive training (CCT), may offer advantages over traditional cognitive rehabilitation (TCR ...
Maria Grazia Maggio +8 more
wiley +1 more source
A Perturbation Subsampling Method for Massive Censored Data. [PDF]
Tian Y, Song J.
europepmc +1 more source
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan +5 more
wiley +1 more source
Robust serotonin activation of the kisspeptin GnRH pulse generator in male and female mice.
Morris PG +7 more
europepmc +1 more source
Small defect detection in printed circuit boards based on the multiscale edge strengthening and an improved YOLOv10. [PDF]
Chen W, Ke X, Meng S.
europepmc +1 more source
Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS
ABSTRACT Objective Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels are believed to reflect mainly acute and chronic disease processes in multiple sclerosis (MS), respectively. In this study, we investigated whether dimethyl fumarate (DMF) and rituximab (RTX) differentially affect these biomarkers.
F. Shawket +14 more
wiley +1 more source
Dataset on the exploratory factor structure of organizational health performance for micro and small enterprises: The initial research stage. [PDF]
Sunarsih U +6 more
europepmc +1 more source
Safety and Tolerability of Givinostat: Evidence From Real‐World and Clinical Practice
ABSTRACT Objective The aim of our study was to establish the prevalence of adverse events in a real‐world setting in boys living with Duchenne muscular dystrophy (DMD) treated with givinostat as part of an Expanded Access Program (EAP) in Italy. Methods The cohort included 90 ambulant boys, with age when treatment started between 6 and 23 years (mean ...
Marika Pane +19 more
wiley +1 more source
Leucine-Rich α2 Glycoprotein as a Predictor of Small Bowel Disease Activity in Crohn's Disease: A Retrospective Study. [PDF]
Hayashi T +17 more
europepmc +1 more source

